Telix raises $398m to advance kidney and brain cancer radiotherapies
Telix is eyeing an expansion of the diagnostic imaging indications for its assets and advancing pivotal trials as the radiopharma arena heats up.
Telix is eyeing an expansion of the diagnostic imaging indications for its assets and advancing pivotal trials as the radiopharma arena heats up.
What's Your Reaction?
